Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].
about
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyCellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor RadiosensitizationDNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerStructure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapiesX-ray structures of checkpoint kinase 2 in complex with inhibitors that target its gatekeeper-dependent hydrophobic pocketBenzimidazole inhibitors of the protein kinase CHK2: Clarification of the binding mode by flexible side chain docking and protein–ligand crystallographyStructural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapyFragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2Targeting of Chk2 as a countermeasure to dose-limiting toxicity triggered by topoisomerase-II (TOP2) poisonsNovel design strategy for checkpoint kinase 2 inhibitors using pharmacophore modeling, combinatorial fusion, and virtual screening.Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures.Superaugmented eccentric distance sum connectivity indices: novel highly discriminating topological descriptors for QSAR/QSPR.Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabineDevelopment of synthetic lethality anticancer therapeutics.Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.Comparative analysis of radiosensitizers for K-RAS mutant rectal cancersCheckpoint kinase Chk2 controls renal Cyp27b1 expression, calcitriol formation, and calcium-phosphate metabolism.The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 InhibitorKinase-independent role for CRAF-driving tumour radioresistance via CHK2AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in Pemetrexed-treated Carcinoma CellsmiR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth.Targeting SOD1 induces synthetic lethal killing in BLM- and CHEK2-deficient colorectal cancer cells.Molecular targets and mechanisms of radiosensitization using DNA damage response pathways.Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.Perspective: Opportunities in recalcitrant, rare and neglected tumors.Agonists of the TRAIL Death Receptor DR5 Sensitize Intestinal Stem Cells to Chemotherapy-Induced Cell Death and Trigger Gastrointestinal ToxicityTargeted regulation of PI3K/Akt/mTOR/NF-κB signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapyCheckpoint kinase inhibitors: a patent review (2009 - 2010).Personalised Medicine: Genome Maintenance Lessons Learned from Studies in Yeast as a Model Organism.CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute.Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.ATR/CHK1 inhibitors and cancer therapy.Directing the use of DDR kinase inhibitors in cancer treatment.Attenuated DNA damage responses and increased apoptosis characterize human hematopoietic stem cells exposed to irradiation.Rare Genetic Diseases with Defects in DNA Repair: Opportunities and Challenges in Orphan Drug Development for Targeted Cancer Therapy
P2860
Q26745686-86617C37-D81F-46D0-97A4-EB59B3BF9550Q26771165-BAD8ED42-7DC5-4724-ABDA-A1D8FCBCEC93Q26776513-84790E70-0EC8-4113-9CD8-16C9E7F5FD8AQ26864870-7B0C546A-3025-46AF-8FB4-216262620906Q27673685-1E34164E-588A-43D9-93AC-23C94715E8F0Q27674450-B6C1890C-8CB2-4B03-87BA-E99E628B3AC1Q27674646-375370EA-3EAA-44FC-8F56-BCF51A49848BQ27678684-201BFB64-E2A0-4AB2-AA15-48840E15BA61Q28828183-1A2E9C71-4D08-4809-9230-2221D9922017Q33597492-1703D41B-9138-4539-BD42-6CA4EA4A54DFQ33952816-D5E4861B-D343-4C1A-83AD-52E85D7D926FQ34052481-C2431C9F-DAB2-4D2C-88A3-A58EA435961DQ34154791-2F299F63-2FAA-4732-9F82-C3814CB22932Q34380368-2F961363-E086-4FAF-A431-1F3B27C8CA2EQ35023976-D5CC21A3-12DD-404E-8CFB-E521EAE14C59Q35070685-08BB8E8F-68A2-4D49-AE2F-339194BA5649Q35335476-3FF13E2C-6C38-4827-A594-DA793ABDC158Q35692130-EBB1C7F1-C151-434E-9C27-A80C80896143Q36027249-EE8C2B95-B601-4514-AE97-4FB495132869Q36282831-4390741B-1D5E-42CE-9077-845FABEEF096Q36341406-D4D30BC9-9D1A-4B1C-99E9-2972ED2C78D8Q36413938-824A8ABC-7734-427E-A3B8-D9199DC1FD71Q36792626-995E195E-9DB8-460D-83D5-D4AD1C9297FAQ37100166-DB2E30C8-AA52-46C5-8DCC-AB67AD3E1174Q37103465-B6D7CD6A-4AF7-4DB1-9349-ACD9D293B028Q37197528-168298EC-8F92-42E1-BB87-3D1ECEE024E8Q37211515-8598C2B8-D9B6-4E12-8583-18BCCBA4DE95Q37512204-588E9451-16FA-4FA3-87D4-F83D490BF48AQ37877694-E86A3F7C-12FD-4E33-A007-33D26DBC7154Q38608688-D2665CE0-AF62-4EE9-BAFA-BC18A954DC3DQ39505275-BD0EDD79-7198-4206-BF68-168DBDCC9C46Q43973311-ECF99D43-B434-43B7-86C4-76F66958C307Q47622968-FFE1A473-E1B5-4D69-9AC1-F953CACC34C2Q47687840-3DF77A6C-41D5-4CA8-9B8B-150DA10951D3Q52718694-8AAB442B-56EA-4465-8982-7A476B21E688Q58773614-4C1F3A8D-A45B-4AFE-972F-5C957B7F1DF2
P2860
Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Cellular Inhibition of Checkpo ...... ole-2-carboxylic acid -amide]
@nl
Cellular inhibition of checkpo ...... razone)-ethyl]-phenyl}-amide].
@ast
Cellular inhibition of checkpo ...... razone)-ethyl]-phenyl}-amide].
@en
type
label
Cellular Inhibition of Checkpo ...... ole-2-carboxylic acid -amide]
@nl
Cellular inhibition of checkpo ...... razone)-ethyl]-phenyl}-amide].
@ast
Cellular inhibition of checkpo ...... razone)-ethyl]-phenyl}-amide].
@en
prefLabel
Cellular Inhibition of Checkpo ...... ole-2-carboxylic acid -amide]
@nl
Cellular inhibition of checkpo ...... razone)-ethyl]-phenyl}-amide].
@ast
Cellular inhibition of checkpo ...... razone)-ethyl]-phenyl}-amide].
@en
P2093
P2860
P3181
P356
P1476
Cellular inhibition of checkpo ...... razone)-ethyl]-phenyl}-amide].
@en
P2093
Akikazu Onda
Andrew G Jobson
Anne Monks
Christopher Self
David Cerna
David S Waugh
Gabriele Zoppoli
George T Lountos
Guangtao Zhang
Jenny Llamas
P2860
P304
P3181
P356
10.1124/JPET.109.154997
P407
P50
P577
2009-09-09T00:00:00Z